Ardian and GHO support MBO of Envision Pharma

The deal values the business in the region of £200-250m, one source told unquote".

It is also understood that Ardian will be the largest shareholder in Envision, though it is not known whether the GP has taken a majority stake.

Upon completion of the deal, the business will launch a new platform, iEnvision Medical Affairs, to support medical compliance and help ensure industry best practice is adhered to. It will also invest in marketing activity.

Capital for the transaction was drawn from Ardian's latest mid-cap buyout fund LBO Fund V, which held a final close on €2.41bn in October 2013.

Company
Founded in 2001 and headquartered in Horsham, West Sussex, Envision provides communications-related marketing services to biopharmaceutical and medical device companies. The business says it has generated average annual growth of 20% since inception.

Envision has additional operations in the US, Japan and Australia.

People
Ardian – Simon Cottle, Bruno Ladriere (managing directors).
GHO Capital – Mark Braganza (partner).
Envision Pharma – Brian Hepburn (CEO, founder); Greg Caswill (chairperson, founder).

Advisers
Equity – Rothschild (M&A); Candesic (commercial due diligence); EY (financial due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• UK / Ireland
• Media
• United Kingdom
• Ardian (formerly Axa PE)